PI-RADS is a standardized 1-to-5 scoring system used by radiologists to describe how likely a prostate MRI lesion is to represent clinically significant prostate cancer. A higher score means greater imaging suspicion: PI-RADS 1 is very low suspicion, PI-RADS 3 is equivocal, and PI-RADS 5 is very high suspicion. The score does not diagnose cancer, does not equal a Gleason score or Grade Group, and does not describe cancer stage. It tells the clinical team how suspicious the MRI appearance is and helps determine whether tissue sampling should be considered.
PI-RADS stands for Prostate Imaging Reporting and Data System. The current PI-RADS v2.1 framework standardizes prostate MRI acquisition, lesion interpretation and reporting. It evaluates the appearance of suspicious tissue on T2-weighted imaging, diffusion-weighted imaging with ADC maps and, when multiparametric MRI is performed, dynamic contrast enhancement. The final category depends partly on whether the lesion is centered in the peripheral zone or transition zone.
01What Does PI-RADS Measure on a Prostate MRI?
PI-RADS measures imaging suspicion for clinically significant prostate cancer
PI-RADS was developed so that prostate MRI reports would use a common language.
Without a standardized system, one radiologist might describe a lesion as “moderately suspicious,” another as “concerning,” and another as “indeterminate,” making it difficult for urologists to know whether the findings represented comparable levels of risk.
PI-RADS organizes that uncertainty into five categories.
The target condition is generally clinically significant prostate cancer, commonly defined in diagnostic studies as ISUP Grade Group 2 or higher disease.
Why does PI-RADS focus on clinically significant cancer?
Not every microscopic prostate cancer has the same clinical importance.
Some Grade Group 1 cancers can remain biologically indolent for years and may be managed with active surveillance rather than immediate treatment.
The modern diagnostic goal is therefore not simply:
“Find every abnormal prostate cell.”
It is more specifically:
“Identify cancers likely to be clinically important while reducing unnecessary biopsy and overdiagnosis of very-low-risk disease.”
Where does PI-RADS fit in the diagnostic process?
PI-RADS sits between the initial suspicion of prostate cancer and tissue diagnosis.
A common pathway is:
PSA or clinical risk → prostate MRI → PI-RADS assessment → targeted biopsy when indicated → pathology.
The entire sequence is explained in How Prostate Cancer Is Diagnosed.
What information reaches the radiologist before a PI-RADS score is assigned?
A prostate MRI should be interpreted in anatomical and clinical context.
Relevant information may include:
- PSA;
- previous PSA values;
- previous biopsy history;
- known prostate cancer;
- prior prostate treatment;
- and the clinical reason for performing MRI.
However, the PI-RADS lesion category itself is primarily an imaging assessment.
Clinical risk is then integrated separately when the urologist decides whether the MRI finding justifies biopsy.
What does PI-RADS evaluate on the MRI?
PI-RADS uses information from the sequences described in Multiparametric Prostate MRI, including:
- T2-weighted anatomy;
- high-b-value diffusion-weighted imaging;
- ADC maps;
- and dynamic contrast enhancement when contrast is used.
These sequences do not all have equal importance in every lesion.
Why does lesion location matter?
The prostate contains different tissue zones.
Two are especially important for PI-RADS:
- peripheral zone: the outer posterior and lateral part of the gland where many prostate cancers arise;
- transition zone: the tissue surrounding the urethra where benign prostate hyperplasia commonly develops.
Normal tissue looks different in these regions.
As a result, the MRI sequence that best separates cancer from benign tissue also differs.
Is PI-RADS the same as the radiologist’s personal opinion?
No.
Radiologist experience still matters, but PI-RADS provides explicit rules for:
- which sequence is dominant;
- how lesions are measured;
- how different prostate zones are evaluated;
- when diffusion changes the score;
- and when dynamic contrast enhancement can modify an equivocal finding.
This standardization is one reason prostate MRI can be integrated into biopsy pathways rather than functioning as a purely subjective scan.
Think of PI-RADS as a radiology probability language. It converts several MRI observations into a standardized level of suspicion so the imaging result can be combined with PSA, prostate volume, family history and other clinical information.
02How Does a Radiologist Decide Whether a Lesion Is PI-RADS 2, 3, 4 or 5?
The first major decision is where the lesion originates
PI-RADS scoring depends heavily on whether the lesion is centered in:
- the peripheral zone;
- or the transition zone.
That is because cancer must be distinguished from different normal and benign backgrounds in each zone.
Peripheral-zone lesions are driven mainly by diffusion
In the peripheral zone, DWI and ADC are the dominant sequences.
Radiologists look for a focal abnormality that is:
- bright on high-b-value diffusion imaging;
- dark on the corresponding ADC map;
- and anatomically coherent with the T2 appearance.
A stronger diffusion abnormality increases suspicion.
What does DCE do in the peripheral zone?
Dynamic contrast enhancement has a narrow but useful modifying role.
Under PI-RADS v2.1:
- a peripheral-zone lesion with DWI score 1 receives overall PI-RADS 1;
- DWI score 2 receives PI-RADS 2;
- DWI score 3 remains PI-RADS 3 when DCE is negative;
- but a qualifying DWI score-3 lesion becomes overall PI-RADS 4 when DCE is positive;
- DWI score 4 remains PI-RADS 4;
- DWI score 5 remains PI-RADS 5.
That is one of the few places where gadolinium contrast can directly alter the overall PI-RADS category.
What counts as positive DCE?
Positive DCE requires focal early or contemporaneous enhancement that corresponds to a suspicious finding on T2 or diffusion imaging.
Diffuse enhancement throughout the gland is not considered the same thing.
This prevents generalized inflammatory enhancement from automatically upgrading a lesion.
Transition-zone lesions are driven mainly by T2 morphology
The transition zone is difficult because BPH creates many nodules.
PI-RADS therefore asks whether a lesion resembles an ordinary BPH nodule or something infiltrative.
Lower-suspicion transition-zone findings include:
- completely encapsulated nodules;
- mostly encapsulated nodules;
- and homogeneous circumscribed nodules with benign morphology.
Higher-suspicion findings become:
- lenticular rather than round;
- non-circumscribed;
- homogeneously moderately hypointense on T2;
- and increasingly invasive in appearance.
How does diffusion modify transition-zone lesions?
T2 remains dominant, but strong diffusion restriction can upgrade certain equivocal transition-zone findings.
Under PI-RADS v2.1:
- a T2 score-2 lesion with very suspicious DWI can rise to overall PI-RADS 3;
- a T2 score-3 lesion with DWI score 5 can rise to overall PI-RADS 4.
DCE does not have the same upgrading role in the transition zone.
What makes a lesion PI-RADS 5 instead of PI-RADS 4?
Size and invasive behavior can move an otherwise highly suspicious lesion into category 5.
Under PI-RADS v2.1, a category-5 type lesion can include the same highly suspicious features used for category 4 but:
- measuring 1.5 cm or larger in greatest dimension;
- or showing definite extraprostatic extension or invasive behavior.
The exact sequence-specific rule depends on the prostate zone.
Does PI-RADS 5 mean cancer has definitely spread outside the prostate?
No.
A lesion can be PI-RADS 5 because of size even when it remains confined to the gland.
Conversely, definite invasive behavior can also make a lesion category 5.
The report should separately describe:
- capsular contact;
- suspected extraprostatic extension;
- seminal-vesicle involvement;
- neurovascular bundle involvement;
- and other local staging findings.
Three systems should never be merged: PI-RADS describes MRI suspicion; Grade Group describes microscopic cancer architecture; TNM staging describes anatomical extent. A patient can have a PI-RADS 5 lesion that ultimately proves benign, or a PI-RADS 4 lesion that biopsy identifies as high-grade cancer.
03What Do PI-RADS 1, 2, 3, 4 and 5 Mean in Practice?
How often does clinically significant cancer occur in each category?
A meta-analysis of PI-RADS v2.1 studies summarized by the EAU reported patient-level detection rates for ISUP Grade Group 2 or higher cancer of approximately:
- 6% for PI-RADS 1;
- 6% for PI-RADS 2;
- 20% for PI-RADS 3;
- 55% for PI-RADS 4;
- 83% for PI-RADS 5.
The median prevalence of clinically significant cancer across those study populations was approximately 43%.
Does a PI-RADS 5 result mean there is an 83% chance for every patient?
No.
The 83% figure is a pooled positive predictive value from a group of studied patients.
An individual’s probability can differ because predictive value changes with:
- PSA density;
- age;
- family history;
- known inherited risk;
- DRE findings;
- previous biopsy history;
- radiologist expertise;
- image quality;
- and the population in which the MRI is being used.
What does PI-RADS 1 mean?
PI-RADS 1 represents very low MRI suspicion.
The prostate appears normal or has no focal lesion meeting suspicious criteria.
But PI-RADS 1 does not mean the probability of significant cancer is literally zero.
Small or MRI-invisible cancers can exist.
What does PI-RADS 2 mean?
PI-RADS 2 represents low suspicion.
Examples can include:
- typical or mostly encapsulated BPH nodules in the transition zone;
- linear or wedge-shaped peripheral-zone T2 changes;
- diffuse mildly abnormal signal;
- or other patterns more typical of benign tissue than focal tumor.
Why are PI-RADS 1 and PI-RADS 2 often grouped as “negative MRI”?
Many clinical pathways define negative MRI as PI-RADS 1–2 because neither category identifies a lesion sufficiently suspicious to routinely require targeted biopsy.
This does not mean biopsy can always be omitted.
A negative MRI must still be interpreted with:
- PSA density;
- DRE;
- family history;
- genetic risk;
- and PSA behavior.
What does PI-RADS 3 mean?
PI-RADS 3 is intentionally an equivocal category.
The radiologist sees an abnormality but the imaging features do not clearly separate clinically significant cancer from benign tissue.
This is the category in which clinical context often has the greatest effect on the next step.
A PI-RADS 3 lesion with:
- PSA density 0.06 ng/mL/cc;
- normal DRE;
- no family history;
- and no inherited high-risk variant
is very different from a PI-RADS 3 lesion in a man with:
- PSA density 0.24 ng/mL/cc;
- progressively rising PSA;
- a suspicious examination;
- or a pathogenic BRCA2 variant.
What does PI-RADS 4 mean?
PI-RADS 4 represents high suspicion that clinically significant prostate cancer is present.
Current EAU pooled evidence places Grade Group 2 or higher cancer detection at approximately 55% overall in this category.
A PI-RADS 4 lesion generally leads to consideration of MRI-targeted biopsy.
What does PI-RADS 5 mean?
PI-RADS 5 represents very high suspicion.
These lesions typically have strongly convincing sequence characteristics and may:
- measure at least 1.5 cm;
- show very marked diffusion restriction;
- or demonstrate definite invasive behavior.
The pooled Grade Group 2 or higher cancer-detection rate is approximately 83%, but pathology remains necessary in most men to determine:
- whether cancer actually exists;
- the Gleason score;
- Grade Group;
- histological subtype;
- and tumor architecture.
Can prostatitis produce PI-RADS 4 or 5 appearances?
Yes.
Inflammatory prostate tissue can produce:
- low T2 signal;
- restricted diffusion;
- low ADC;
- and contrast enhancement.
Some inflammatory lesions can therefore look highly suspicious.
A scan cannot reliably classify every such case without tissue confirmation.
Can BPH create a high PI-RADS lesion?
Benign transition-zone nodules are one of the major challenges in prostate MRI.
Typical well-encapsulated nodules are usually recognized as benign, but atypical stromal nodules can:
- have low T2 signal;
- restrict diffusion;
- and lack a perfectly typical capsule.
These can create false-positive findings.
Can a low PI-RADS score still contain aggressive cancer?
Yes, although the probability is lower.
MRI is highly sensitive for clinically significant disease but not perfect.
For this reason, persistently concerning PSA or inherited risk should not be discarded solely because an MRI is PI-RADS 1 or 2.
The PI-RADS category is not the patient’s final cancer probability. It is the imaging component of that probability. PSA density can shift a low-score MRI toward concern or make an equivocal lesion sufficiently low risk to monitor.
04How Does PI-RADS Change the Decision to Perform a Prostate Biopsy?
PI-RADS and PSA density are independent risk signals
One of the most clinically useful advances in prostate MRI is combining the MRI category with PSA density.
PSA density adjusts the blood PSA concentration for prostate size:
PSA density = PSA ÷ prostate volume.
Because MRI measures prostate volume, the same scan that generates the PI-RADS score can also improve interpretation of the PSA blood test.
How much can PSA density change risk within the same MRI category?
In the EAU risk table derived from biopsy-naïve men, the estimated prevalence of Grade Group 2 or higher cancer varied substantially according to both PI-RADS category and PSA density.
What does current EAU guidance recommend after PI-RADS 1 or 2?
When MRI is negative—PI-RADS 1 or 2—and clinical suspicion is low, EAU guidance allows biopsy to be omitted with PSA monitoring.
The guideline’s low-suspicion example includes:
- PSA density below 0.20 ng/mL/cc;
- and no important prostate-cancer family history.
This is a weak recommendation because biopsy decisions still require individual clinical judgment.
What happens after PI-RADS 3?
PI-RADS 3 is where risk integration becomes especially important.
EAU guidance allows biopsy to be omitted when clinical suspicion is very low, including:
- PSA density below 0.10 ng/mL/cc;
- and no meaningful family-history concern.
Otherwise, targeted biopsy with perilesional sampling can be considered.
What happens after PI-RADS 4 or 5?
Current EAU guidance recommends combining targeted biopsy with perilesional sampling when MRI is positive at PI-RADS 4 or higher.
The goal is to:
- sample the center of the suspicious lesion;
- sample immediately adjacent tissue;
- reduce the chance that the needle misses a high-grade component;
- and obtain enough tissue for accurate pathological grading.
Does PI-RADS 5 ever eliminate the need for biopsy?
Usually no.
A PI-RADS 5 lesion still cannot provide:
- histological proof of malignancy;
- Gleason pattern;
- Grade Group;
- percentage pattern 4;
- cribriform status;
- or other pathology details needed for treatment planning.
Only unusual clinical situations with overwhelming evidence of advanced malignancy and circumstances in which tissue confirmation would not change management may lead clinicians to omit biopsy.
What if the MRI is negative but PSA continues rising?
A negative MRI should not automatically stop the investigation.
The clinician may reconsider:
- whether PSA was repeated;
- prostate volume;
- PSA density;
- family history;
- DRE;
- previous biopsy results;
- genetic risk;
- and MRI technical quality.
The practical route after persistent PSA concern is covered in What Happens After a High PSA?.
How is PI-RADS different from PSA?
The two tests measure different parts of the diagnostic problem.
PSA is a blood biomarker generated by prostate tissue.
PI-RADS describes what suspicious tissue looks like on MRI.
Neither replaces the other.
For a direct comparison, see PSA vs Prostate MRI.
Does inherited risk still matter after MRI?
Yes.
A pathogenic BRCA2 variant, a strong multigenerational family history or other established inherited risk can increase the baseline probability of clinically significant disease.
That is why the MRI result should be interpreted inside the broader prostate cancer risk profile, rather than in isolation.
The practical rule is simple: PI-RADS tells you how suspicious the picture is; PSA density and clinical risk tell you how worried to be about that picture; biopsy tells you what the tissue actually is.
→PI-RADS 1–5: Practical Interpretation Table
| PI-RADS category | MRI meaning | EAU pooled GG ≥2 detection | Common clinical interpretation | What it does not mean |
|---|---|---|---|---|
| PI-RADS 1 | Very low likelihood of clinically significant cancer. | About 6% | Usually reassuring; integrate PSA density and clinical risk. | “Cancer is impossible.” |
| PI-RADS 2 | Low likelihood. | About 6% | Often monitored without immediate biopsy when the rest of the risk profile is low. | “The prostate is completely normal.” |
| PI-RADS 3 | Intermediate / equivocal. | About 20% | Biopsy decision strongly influenced by PSA density, family history and other risk factors. | “50/50 chance of cancer” or Grade Group 3. |
| PI-RADS 4 | High likelihood. | About 55% | Targeted biopsy generally considered; EAU recommends targeted plus perilesional sampling for MRI-positive PI-RADS ≥4. | Stage 4 prostate cancer. |
| PI-RADS 5 | Very high likelihood. | About 83% | Strong biopsy indication in most diagnostic settings. | Certain cancer, Grade Group 5 or “stage 5” cancer. |
?Common Questions About PI-RADS
| Question | Practical answer |
|---|---|
| What does PI-RADS stand for? | Prostate Imaging Reporting and Data System. |
| What does PI-RADS measure? | The MRI likelihood that a prostate lesion represents clinically significant prostate cancer. |
| What is the current PI-RADS version? | PI-RADS v2.1 is the current widely used framework. |
| Is PI-RADS a cancer diagnosis? | No. It is an imaging assessment category. |
| Is PI-RADS the same as Gleason score? | No. Gleason score is determined microscopically from prostate cancer tissue. |
| Is PI-RADS the same as Grade Group? | No. Grade Group 1–5 is a pathology grading system, not an MRI scoring system. |
| Is PI-RADS 4 stage 4 cancer? | No. PI-RADS 4 means high MRI suspicion; stage 4 describes advanced anatomical spread of confirmed cancer. |
| Is there stage 5 prostate cancer because PI-RADS goes to 5? | No. PI-RADS 5 is an imaging category, not a prostate-cancer stage. |
| What does PI-RADS 1 mean? | Very low MRI likelihood of clinically significant prostate cancer. |
| What does PI-RADS 2 mean? | Low MRI likelihood of clinically significant prostate cancer. |
| What does PI-RADS 3 mean? | The MRI finding is equivocal; clinical risk factors become particularly important. |
| What does PI-RADS 4 mean? | Clinically significant prostate cancer is considered likely on imaging. |
| What does PI-RADS 5 mean? | Clinically significant prostate cancer is considered highly likely on imaging. |
| What percentage of PI-RADS 3 lesions are significant cancer? | EAU pooled PI-RADS v2.1 data report about 20% at patient level, although risk changes substantially with PSA density and population. |
| What percentage of PI-RADS 4 lesions are significant cancer? | EAU pooled data report about 55% Grade Group 2 or higher cancer. |
| What percentage of PI-RADS 5 lesions are significant cancer? | EAU pooled data report about 83% Grade Group 2 or higher cancer. |
| Can PI-RADS 5 be benign? | Yes. A minority of highly suspicious lesions ultimately prove benign or non-malignant on tissue sampling. |
| Can prostatitis be PI-RADS 4 or 5? | Inflammation can mimic highly suspicious cancer features, including low T2 signal, diffusion restriction and enhancement. |
| Can BPH look like PI-RADS 4? | Yes. Some atypical transition-zone nodules can mimic cancer. |
| Can PI-RADS 1 or 2 still contain cancer? | Yes. MRI reduces risk but cannot eliminate it. |
| What counts as a negative prostate MRI? | Many clinical pathways define PI-RADS 1–2 as negative MRI. |
| What counts as a positive prostate MRI? | Thresholds vary by pathway, but current EAU biopsy recommendations treat PI-RADS 4 or higher as clearly positive for targeted plus perilesional sampling, while PI-RADS 3 is handled according to overall risk. |
| Does PI-RADS 3 need biopsy? | Sometimes. PSA density, family history, DRE, inherited risk and prior biopsy information help determine whether to biopsy or monitor. |
| Can a PI-RADS 3 lesion be monitored? | Yes. EAU allows PSA monitoring instead of biopsy when clinical suspicion is very low, including PSA density below about 0.10 ng/mL/cc and no family history. |
| Does PI-RADS 4 need biopsy? | Biopsy is generally appropriate in the diagnostic setting. Current EAU guidance recommends targeted and perilesional sampling for PI-RADS 4 or higher. |
| Does PI-RADS 5 need biopsy? | Usually yes, because tissue is needed to confirm malignancy and determine Grade Group. |
| What is the dominant MRI sequence in the peripheral zone? | DWI/ADC. |
| What is the dominant sequence in the transition zone? | T2-weighted morphology. |
| Can contrast change the PI-RADS score? | Yes in selected peripheral-zone lesions. A qualifying DWI score-3 lesion can become overall PI-RADS 4 when matching DCE is positive. |
| Does contrast matter equally in the transition zone? | No. T2 morphology and diffusion drive transition-zone scoring; DCE does not play the same upgrading role. |
| Why does 1.5 cm matter? | For certain otherwise highly suspicious sequence findings, a greatest dimension of 1.5 cm or more is part of the category-5 criterion. |
| Does PI-RADS 5 mean the tumor has left the prostate? | Not necessarily. Size alone can create category 5, although definite extraprostatic extension can also qualify. |
| What is PSA density? | Serum PSA divided by prostate volume. It materially changes cancer probability within each MRI category. |
| Can a negative MRI with high PSA density still need biopsy? | Yes. High PSA density can leave substantial residual risk despite PI-RADS 1–2 imaging. |
| Does BRCA2 affect how PI-RADS is interpreted? | The MRI category itself is assigned from imaging, but BRCA2 increases baseline cancer risk and therefore affects the clinical significance of the result. |
| Can PI-RADS be used to choose treatment? | It can contribute anatomical information, but treatment decisions require confirmed pathology, Grade Group, stage, PSA and patient-specific factors. |
ΣKey Clinical Takeaways
- PI-RADS stands for Prostate Imaging Reporting and Data System.
- PI-RADS v2.1 is the current widely used prostate MRI reporting framework.
- The score estimates MRI suspicion for clinically significant prostate cancer.
- It ranges from 1 to 5.
- PI-RADS 1 represents very low suspicion.
- PI-RADS 2 represents low suspicion.
- PI-RADS 3 is equivocal or intermediate.
- PI-RADS 4 represents high suspicion.
- PI-RADS 5 represents very high suspicion.
- PI-RADS is not a cancer diagnosis.
- PI-RADS is not Gleason score.
- PI-RADS is not ISUP Grade Group.
- PI-RADS is not cancer stage.
- A PI-RADS 4 lesion does not mean stage 4 prostate cancer.
- A PI-RADS 5 lesion does not mean Grade Group 5 or “stage 5.”
- Diffusion imaging is dominant for peripheral-zone lesions.
- T2 morphology is dominant for transition-zone lesions.
- DCE has a supportive upgrading role in selected peripheral-zone findings.
- A peripheral-zone DWI score-3 lesion can become PI-RADS 4 when qualifying DCE is positive.
- Strong diffusion restriction can upgrade certain transition-zone lesions.
- Size of 1.5 cm or more can be part of a PI-RADS 5 criterion.
- Definite extraprostatic extension or invasive behavior can also produce category 5.
- EAU pooled Grade Group 2 or higher cancer detection is approximately 6%, 6%, 20%, 55% and 83% for PI-RADS 1 through 5.
- Those percentages are population estimates rather than personal probabilities.
- PSA density substantially modifies the meaning of the MRI category.
- In EAU risk data, PI-RADS 1–2 with PSA density below 0.10 had about 3% Grade Group 2 or higher cancer prevalence.
- The same PI-RADS 1–2 group with PSA density above 0.20 had about 18% prevalence.
- PI-RADS 3 ranged from about 4% with PSA density below 0.10 to about 29% in higher PSA-density groups in the cited dataset.
- PI-RADS 4–5 risk rose from about 31% with PSA density below 0.10 to about 77% above 0.20.
- Selected men with PI-RADS 1–2 and low overall risk can avoid immediate biopsy.
- Selected very-low-risk PI-RADS 3 findings can also be monitored.
- PI-RADS 4–5 generally justify targeted biopsy in the diagnostic setting.
- EAU recommends targeted plus perilesional sampling when MRI is PI-RADS 4 or higher.
- Prostatitis can mimic cancer on MRI.
- BPH nodules can mimic cancer in the transition zone.
- A negative MRI cannot eliminate clinically significant cancer.
- A highly positive MRI cannot prove malignancy without tissue in most patients.
- The strongest interpretation combines PI-RADS with PSA density, family history, inherited risk, DRE and prior biopsy information.
Clinical bottom line: PI-RADS is a standardized MRI suspicion score, not a diagnosis. It translates prostate MRI findings into a common five-level language so clinicians can judge whether a lesion is sufficiently suspicious to biopsy. The score becomes much more useful when paired with PSA density and the patient’s baseline cancer risk. PI-RADS 1–2 can support monitoring in appropriately low-risk men, PI-RADS 3 requires individualized risk interpretation, and PI-RADS 4–5 generally move the diagnostic pathway toward targeted tissue sampling. The final question—whether cancer is actually present and how aggressive it is—still belongs to pathology.
Medical disclaimer: This article provides general medical education about PI-RADS and prostate MRI. A PI-RADS score cannot determine an individual’s diagnosis or biopsy need by itself. PSA history, prostate volume, PSA density, family history, genetic risk, DRE findings, previous biopsy results, MRI technical quality and radiologist expertise all affect clinical interpretation.
For the complete pathway from initial suspicion through MRI, biopsy and pathology, see How Prostate Cancer Is Diagnosed. For how the scan itself creates anatomical and functional images, see What Is a Prostate MRI? and Multiparametric Prostate MRI. Because the MRI score becomes much more informative when prostate size is added to the blood marker, see PSA Density and PSA vs Prostate MRI. For inherited or family-based risk that can change the importance of a negative or equivocal scan, see Prostate Cancer Risk Factors and BRCA1, BRCA2 and Prostate Cancer. For the complete prostate-cancer pathway, return to the Prostate Cancer hub. The next guide examines prostate nodules, including what a nodule on examination or imaging can mean and why a prostate nodule is not automatically cancer.
Evidence Sources
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: PI-RADS v2.1 cancer-detection rates, PSA-density risk matrix, MRI interpretation and biopsy recommendations.
- American College of Radiology — PI-RADS: official current resources for standardized prostate MRI acquisition, interpretation and reporting.
- ACR, ESUR and AdMeTech Foundation — PI-RADS v2.1: official scoring criteria for peripheral-zone and transition-zone lesions, DWI, T2 and DCE.
- American College of Radiology — PI-RADS v2.1 revisions: updated transition-zone scoring and dynamic contrast-enhancement criteria.
- American Urological Association / Society of Urologic Oncology — Early Detection of Prostate Cancer: MRI, risk assessment and biopsy decision-making.
- National Cancer Institute — Prostate-Specific Antigen Test: PSA interpretation and limitations relevant to MRI-based prostate-cancer evaluation.
